Generex Biotechnology (GNBTQ) 10-Q2008 Q1 Quarterly report

Filed: 7 Dec 07, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: Abbott, abnormally, Adcock, aerosol, Africa, African, announced, Armenia, assist, avoidance, BaBOOM, Bentley, blood, candidate, CDSCO, Central, clearance, complexity, comply, concurrently, costly, country, created, deferral, derecognition, device, disappointing, discontinue, dossier, dry, ease, Ecuadorian, efficacy, EMEA, Emisphere, energy, enrolling, enrollment, European, examination, experimental, extant, extensive, formulary, frequent, geographic, Georgia, GlucoBreak, handled, high, IGT, importation, India, Indian, Ingram, injectable, insufficient, intact, issuable, Jordan, Kazakhstan, key, Kos, Kuwait, largest, licensee, line, mannkind, meal, mentioned, monitoring, neighboring, newly, Nordisk, novelty, Novo, obsolete, panel, population, portability, prescription, proceed, progression, prophylactic, Pty, pulmonary, Pvt, Qatar, RapidMist, ready, regular, reliable, Republic, resold, rest, role, satisfaction, Shreya, sponsorship, spray, Submission, table, Technosphere, threshold, Tolerance, traction, transition, transitioning, type, uncertain, uncompetitive, underway, Union, unrestricted, unvested, valuation, viable, world, Yemen

Removed: accelerated, acceleration, accrual, accrue, alleging, AmerisourceBergen, amortization, amortize, amortized, Ananindeau, answer, assured, bad, banking, began, Black, Cardinal, carry, collateral, collectibility, collection, conclude, confectionary, converted, coupon, credit, Custodial, custodian, customer, daily, declared, Default, demanded, determinable, discount, divided, doubtful, education, EITF, evidence, expanded, Feldman, FIFO, fifteen, holder, implemented, incomplete, independent, initially, introduced, iv, Latin, law, lesser, liquidated, Mandatory, maximum, McKesson, met, month, monthly, multiplied, NASD, ninety, noncomparability, occurrence, overdue, owing, persuasive, predetermined, prepaid, Prepayment, previously, principal, public, published, qualified, registered, resale, run, San, Security, shipped, spend, sum, thereon, thirteen, title, trade, training, twenty, unamortized, uncollectible, understand, unpaid, unsold, varying, vesting, volume, VWAP, Weinstein, written

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

GNBTQ similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32

CERTIFICATIONS

Pursuant to Section 906 of the Public Company Accounting Reform and Investor Protection Act of 2002 (18 U.S.C. ss. 1350, as adopted), Anna E. Gluskin, Chief Executive Officer and President of Generex Biotechnology Corporation (the "Company"), and Rose C. Perri, Chief Financial Officer of the Company, each hereby certifies that, to the best of her knowledge:

1. The Company’s Quarterly Report on Form 10-Q for the period ended October 31, 2007 as filed with the United States Securities and Exchange Commission and to which this Certification is attached as Exhibit 32 (the "Report"), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



DATE: December 7, 2007	By:	/s/ Anna E. Gluskin
		Anna E. Gluskin, Chief Executive Officer
		(Principal Executive Officer)


DATE: December 7, 2007	By:	/s/ Rose C. Perri
		Rose C. Perri, Chief Financial Officer
		(Principal Financial and Accounting Officer)